Transcatheter aortic valve implantation (TAVI) is now an established treatment option for elderly patients with severe ...

Traditional operative risk calculators, such as the European System for Cardiac Operative Risk Evaluation II (EuroSCORE II), ...

The MiRus Siegel™ Valve was featured in three podium presentations at the NY Valves meeting last week. Pradeep K. Yadav MD, ...

Dapagliflozin reduced the risk of all-cause mortality or worsening heart failure by 28% in patients with aortic stenosis ...

In EARLY TAVR, intervention improved outcomes over waiting in patients with class II or no indications for AVR consideration.

Introduction Aortic stenosis (AS) is the most common valvular heart disease in the western world. As a predominantly degenerative process the disease prevalence increases with age, affecting 4% of ...

Aortic stenosis (AS), a common condition affecting 3% of individuals aged >75 years, leads to heart failure and death unless the valve is replaced. 1 Recently, patients with concomitant degenerative ...

In a world defined by macroeconomic uncertainty and shifting geopolitical realities, Pella continues to find opportunities.

There is currently no way to stop calcification of the aortic valve. If all else fails, the valve must be replaced. To better ...

In DETECT AS, the passive notifications improved rates of AVR and boosted survival, with bigger gains in women.